BrightGene Bio-Medical Hits Day High with 4.4% Surge Amid Market Decline

BrightGene Bio-Medical Technology Co., Ltd. has experienced a notable increase of 4.4% on February 27, 2026, reaching an intraday high of CNY 46.95. This performance stands in contrast to the China Shanghai Composite, which declined by 1.26% on the same day. Over the past week, BrightGene's stock has shown a modest gain of 1.04%, while its monthly performance reflects a decline of 7.19%. In terms of annual performance, BrightGene has achieved a return of 22.91%, slightly outperforming the China Shanghai Composite's 22.49%. However, year-to-date, the stock has faced challenges, with a decline of 6.62%. Despite these fluctuations, the company has been grappling with significant financial metrics, including a high debt-to-equity ratio of 0.72 and a price-to-earnings ratio of 386.00. The return on equity stands at 1.27%, indicating low profitability relative to shareholder funds. BrightGene's market capitalization is CNY 19,155 million, positioning it as a large-cap player in the pharmaceuticals and biotechnology sector.